|
|
|
|
|
Brimonidine
drug data and news
Brimonidine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Brimonidine | ||
| Brand Names/Synonyms | Alphagan; Alphagan P; Brimonidine; Brimonidine Tartrate; Bromoxidine; CHEMBANK1623 | ||
| Indication | For the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Brimonidine significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. It lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow. | ||
| Mechanism Of Action | Brimonidine is an alpha adrenergic receptor agonist. It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. | ||
| Brimonidine News (When available) |
| ||
| Dosage Forms | 0.2% solution | ||
| Drug_Category | Antihypertensive Agents; EENT Drugs; ATC:S01EA05 | ||
| Absorption | Minimal systemic absorption occurs after ocular insertion. | ||
| Interactions |
-->Interactions for Brimonidine: Although specific drug interaction studies have not been conducted with ALPHAGAN® P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. Alpha-agonists, as a class, may reduce pulse and blood pressure. Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised. Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN® P in humans can lead to resulting interference with the IOP lowering effect. No data on the level of circulating catecholamines after ALPHAGAN® P administration are available. Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines. | ||
| Toxicity | Oral LD50 is 50 mg/kg in mice and 100 mg/kg in rats. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine | ||
| Chemical Formula | C11H10BrN5 | ||
| Molecular Weight | 292.135 g/mol | ||
| Smiles String | C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br | ||
| Melting Point | 207.5 °C | ||
| Water Solubility | Soluble (1.5 mg/mL) | ||
| State | Yellow crystals from ethanol | ||
| LogP/Hphobicity | 0.782 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Metabolized primarily by the liver. | ||
| Half Life | 2 hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Brimonidine.html http://www.rxlist.com/cgi/generic3/alphagan-p.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00034 | ||
| CAS Registry Number | 59803-98-4 | ||
| KEGG Compound ID | C07886 | ||
| PubChem ID | SID:213378 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2243026 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |